200 results about "Sacroiliitis" patented technology

A Chinese medicine for treating cervical spondylopathy, periomethritis, lumbar intervertebral disc protrusion and hyperosteogeny is prepared from 79 Chinese-medicinal materials including centipede, ground beetle, Chuan-xiong rhizome, myrrh, etc. Its preparing process is also disclosed.

Monoclonal antibodies are identified that bind the IL-21 protein. These antibodies are used to identify regions of the IL-21 protein to where binding neutralizes IL-21 activity. Hybridomas and methods of producing anti-IL-21 monoclonal antibodies are described. The monoclonal antibodies are useful in treating IL-21-mediated diseases, which may include autoimmune and inflammatory diseases such as pancreatitis, type I diabetes (IDDM), Graves Disease, inflammatory bowel disease (IBD), Crohn's Disease, ulcerative colitis, irritable bowel syndrome, multiple sclerosis, rheumatoid arthritis, diverticulosis, systemic lupus erythematosus, psoriasis, ankylosing spondylitis, scleroderma, systemic sclerosis, psoriatic arthritis, osteoarthritis, atopic dermatitis, vitiligo, graft vs. host disease (GVHD), cutaneous T cell lymphoma (CTCL), Sjogren's syndrome, glomerulonephritis, IgA nephropathy, graft versous host disease, transplant rejection, atopic dermatitis, anti-phospholipid syndrome, and asthma, and other autoimmune diseases.

The invention relates to methods to identify compounds that can treat autoimmune conditions and treat specified clinical disorders such as multiple sclerosis, ulcerative colitis or arthritis. Compounds include 17α-ethynylandrost-5-ene-3β,15β,7α,17β-tetrol, 4α-acetoxy-17α-ethynylandrost-5-ene-3β,7β,17β-triol, 17α-ethynylandrost-5-ene-3β,4β,7α,17β-tetrol, 17α-ethynylandrost-5-ene-3α,4β,7α,17β-tetrol and 17α-ethynylandrost-5-ene-3α,4β,17β-triol-7-one.

The present invention relates to compounds of Formula (I),methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury / loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

The present invention provides a method of determining, in a sample, the proportion of a total amount of a molecule that is derived from catabolism due to the presence of age-related molecular alterations on the molecule, comprising: a) determining the total amount of the molecule in the sample; b) determining the amount of the molecule in the sample that contains D-aspartate; and c) calculating the proportion of the amount of the molecule of step (b) relative to the total amount of the molecule as determined in step (a), thereby determining the proportion of the total amount of the molecule that is derived from catabolism due to the presence of age-related molecular alterations in the molecule. Further provided is a method of diagnosing a musculoskeletal, arthritic or joint disorder in a subject and / or identifying a subject at risk for developing such a disorder, comprising: a) measuring an amount of D-aspartate and / or an advanced glycation end product in a sample of the subject; and b) comparing the amount of D-aspartate and / or advanced glycation end product in the sample of (a) with an amount of D-aspartate and / or advanced glycation end product in a sample of a control subject, whereby an increased amount of D-aspartate and / or advanced glycation end product in the sample of the subject as compared to the amount of D-aspartate and / or advanced glycation end product in the sample of the control subject is diagnostic of a musculoskeletal, arthritic or joint disorder in the subject and / or identifies a subject at risk of developing such a disorder.

The anthranilic acid derivative or the salt thereof represented by the general formulawherein R1 and R2 are hydrogen atom, or the like; R3 is a phenyl, cycloalkyl or bicyclic heterocyclic group which may be substituted, or the like; R4 is a phenyl, cycloalkyl or pyridyl group which may be substituted, or the like; X1 is an alkylene or alkenylene group which may be substituted or a bond; X2 is the general formula -X3-X4- or -X4-X3-, wherein X3 is a sulfur atom, an imino group or a bond, or the like; X4 means an alkylene or alkenylene group which may be substituted or a bond; is useful for a remedy such as rheumatoid arthritis, osteoarthritis and carcinoma, because it shows MMP-13 production inhibitory effect.

The invention relates to a plaster used for treating rheumatism, rheumatoid disease and various hyperosteogeny, which consists of 35 kinds of Chinese medicine materials, including nux vomica, unprocessed radix aconiti, unprocessed wild aconite, clematis chinensis, Chuanmugua, radix cyathulae, common culbmoss herb, Chuanduan, divaricate sapshnikovia root, cassia twig and ephedra, etc. The plaster has the functions of eliminating dampness, dispelling cold, activateing collaterals, promoting blood circulation by removing blood stasis, reducing swelling and resolving masses. Therefore, the plaster has the good effects on rheumatism, rheumatoid disease, prolapse of lumbar intervertebral disc, cervical spondylosis, gonarthritis, hyperosteogeny and hyperplasia of mammary glands and no toxicity and side effects. In addition, curative effect is quick, the course of treatment is short and cure rate is high.

The present invention relates to a compound represented by the formula [I]wherein X1, X2 and X3 are each an optionally substituted CH or a nitrogen atom, and any one of X1, X2 and X3 is a nitrogen atom, X4 is an optionally substituted CH, R1 is an optionally substituted phenyl group or an optionally substituted heterocyclic group, and R2 is an optionally substituted pyridin-4-yl group, an optionally substituted pyridine-N-oxide-4-yl group or an optionally substituted pyrimidin-4-yl group, or a salt thereof. The compound has superior p38 MAP kinase inhibitory activity and MMP-13 production inhibitory activity, and is useful as an agent for the prophylaxis or treatment and the like of an inflammatory disease, an autoimmune disease, a debilitating disease, an osteoarticular degenerative disease, a neurodegenerative disease, a vascular disease, a neoplastic disease or an infectious disease.

The present invention relates to novel heterocyclic compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof. The present invention more particularly provides novel hetereocycles of the general formula (I). Also included is a method of treatment of immunological diseases, inflammation, pain disorder, rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; ischemic heart disease; atherosclerosis; cancer; ischemic-induced cell damage; pancreatic beta cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; muscle degeneration; cachexia; asthma; bone resorption diseases; ischemia reperfusion injury; brain trauma; multiple sclerosis; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection in a mammal comprising administering an effective amount of a compound of formula (I) as described above.

The present invention discloses one kind of arthritis treating Chinese medicine composition and its preparation process. The Chinese medicine composition contains the effective components of frankincense, myrrh, safflower, curcuma, clematis root and other six kinds of Chinese medicinal materials, and may be prepared into granule, tablet, capsule or other pharmaceutical preparation form. It has the functions of promoting blood circulation to disperse blood clots, dredging meridian and relieving pain, and may be used in treating rheumatic arthritis, rheumatoid arthritis, bone arthrosis, gout and ankylosing spondylitis.

The present disclosure is directed to modulators of cyclooxygenase (COX) enzymes and pharmaceutically acceptable salts and prodrugs thereof, the chemical synthesis thereof, and the medical use of such compounds for the treatment and / or management of the severity and duration of non-specific pain, tension-type pain, headache, migraine, lower back pain, sciatica, dental pain, muscular pain, pain associated with acute soft tissue injuries, bursitis, tendonitis, lumbago, periarthritis, tennis elbow, sprains, strains, muscular problems associated with sports injuries, muscular problems associated with accidents, period pain, primary dysmenorrhoea, acute sore throat pain, osteoarthritis, rheumatoid arthritis, cancer, any disorder requiring analgesic response, any disorder requiring anti-inflammatory response, any disorder requiring antipyretic response, any conditions mediated by cyclooxygenase, cystic fibrosis, dementia, Alzheimer's disease, and / or conditions mediated by levels of β-amyloid are described.

Compounds described by the chemical formula (I) or pharmaceutically acceptable salts thereof:are inhibitors of p38 and are useful in the treatment of inflammation such as in the treatment of asthma, COPD, ARDS, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; inflamed joints, eczema, psoriasis or other inflammatory skin conditions such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis, pain and other conditions associated with inflammation.

The present invention is related to a bilayer pharmaceutical composition comprising naproxen or a pharmaceutically acceptable salt thereof. The present invention is particularly related to a bilayer pharmaceutical composition comprising an immediate release component and a controlled release component of naproxen or a pharmaceutically acceptable salt thereof and the process for preparation thereof. Moreover, the present invention is related to the treatment of rheumatoid arthritis, oesteoarthritis, ankylosing spondylitis, pain, primary dysmenorrhoea, acute tendinitis, bursitis and acute gout.

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-cycloalkyl compounds of the following formula (collectively referred to herein as “APSAC compounds”). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in treatment, for example, of inflammation and / or joint destruction and / or bone loss; of disorders mediated by excessive and / or inappropriate and / or prolonged activation of the immune system; of inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like; of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, Paget's disease and the like, etc.; and of cancer, such as a haematological malignancy, a solid tumour, etc. Formula (I).

The present invention relates to compounds of Formula (I),methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury / loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

The invention encompasses a method for diagnosing an arthritic condition and a gastrointestinal inflammatory disorder in a companion animal. The invention also encompasses a method for identifying ingredients for a pet food composition that are suitable for preventing, ameliorating the symptoms of, or treating an arthritic condition or gastrointestinal inflammatory disorder.

The present invention is a kind of Chinese medicine preparation prepared with safflower, drynaria rhizome, leatherleaf milletia and clematis root in certain weight proportion, and through organic solvent extraction or direct crushing and other conventional steps. The Chinese medicine preparation may be prepared into liniment, tincture, ointment, plaster and other externally applied preparation forms. Its is used in treating pain caused by hyperosteogeny, protrusion of lumbar intervertebral disc, cervical spondylopathy, etc. through being applied to the pain spot, and has high curative effect.

A glove for reducing lateral subluxation of the first carpometacarpal joint that includes a glove body, and a strap portion carried by the glove body. The strap portion extends from a proximal end portion of the glove, and has a length sufficient to allow the strap to be looped around the thumb, to provide dorsal-radial tension on the thumb near the distal end of the first metacarpal in order to reduce lateral subluxation at the first carpometacarpal joint. An attachment element is also provided for securing a distal end of the strap portion to a mutually engaging attachment element secured to the glove body.

This invention generally relates to methods for the treatment of IL-23 related diseases, in particular inflammatory diseases, such as psoriasis, psoriatic arthritis or axial (spinal) spondyloarthritis (ax-SpA), including ankylosing spondylitis and non-radiographic ax-SpA, utilizing anti-IL-23A antibodies.

The invention discloses granules for relieving the stasis of blood and removing the obstruction of vital energy and blood flow in the chest. The granules are prepared from 35-42g of giant mistletoe, 35-42g of pubescent angelica root, 35-42g of radix gentianae macrophyllae, 35-42g of radix sileris, 28-35g of pawpaw, 7-11g of wild ginger, 35-42g of eucommia bark, 35-42g of radix cyathulae, 22-28g oftripterygium wilfordii, 42-52g of caulis lonicerae, 42-52g of caulis sinomenii, 35-42g of caulis piperis kadsurae, 35-42g of wooly datchmanspipe herb, 57-67g of astragalus root, 28-35g of tuckahoe, 35-42g of angelica, 28-35g of rhizoma ligustici wallichii, 35-42g of white peony root, 42-52g of radix salviae miltiorrhizae, 15-23g of scaly anteater, 28-35g of cassia nomame thorn and 12-20g of licorice (moxibustion). The preparation method of the granules comprises the following steps: adding water into the twenty two traditional Chinese medicines, decocting for 1.5 hours for the first time anddecocting for 1 hour for the second time by adding water, merging decoction, filtering, decompressing and concentrating filtrate into thick paste with the relative density of 1.35-1.40 (60 DEG C), decompressing and drying, and pulverizing into fine powder; taking the fine powder, adding an amount of sucrose powder, dextrin and ethanol, preparing granules and subpackaging. The granules are convenient to take, have the effects of tonifying the liver and the kidney, strengthening the bone and tendons, relieving the stasis of blood, removing pathologic wind and relieving pains and have very goodcurative effect to rheumatoid arthritis, tetanic dorsal column inflammation, sacroiliitis and the like.

Disclosed is an externally applied pure Chinese medicine for treating spondylitis ankylopoietica and arthritis, which comprises the following Chinese medicinal materials (by weight portion), musk 2-35, wild aconkite root 2-30, Clematis chinensis 2.5-40 and seed of nuxvomica 2-40.

The invention provides a micro RNA group related to Th17 differentiation. The micro RNA group comprises micro RNA 4426, micro RNA 3615, micro RNA 106b, micro RNA 590 and micro RNA 573. The micro RNA changes remarkably in the Th17 differentiation process and can be used as Th17 control targets for preparing drugs for treating or preventing Th17-related diseases including lupus erythematosus, dermatomyositis, vasculitis, sicca syndromes, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, scleroderma, multiple sclerosis, malaria, solar dermatitis, eczema, leucoderma, psoriasis, atopic dermatitis, lichen planus, diabetes, coronary heart diseases, hyperlipemia and the like. The micro RNA group is sensitive to hydroxychloroquine intervention and can serve as a sensitive index for judgment of the clinical effect of hydroxychloroquine, and the micro RNA is convenient to test clinically and can be rapidly used for judging the clinical effect of hydroxychloroquine.

A preparation method of volcanic mud black ointment, which is composed of 20-30% of medicinal pills prepared from Chinese herbal medicines, 10-20% of medicinal vaseline, 50-60% of volcanic mud and 10-20% of vegetable oil. Hot compress of mud black ointment on the lesions of the body can quickly open up the meridians of the whole body, promote blood circulation in the body, and treat waist and leg pain, hip joint disease, internal rheumatoid arthritis, ankylosing spondylitis, osteoporosis, lumbar disc herniation, cervical spondylosis and bone hyperplasia.

The problem of the present invention is to provide a compound having a superior RORγt inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like. The present invention relates to a compound represented by the formula (I):[wherein each symbol is as described in the DESCRIPTION] or a salt thereof, which has an RORγt inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like.

The present invention relates to a method for preparing a cartilage product comprising a protein hydrolysate with a degree of hydrolysis comprised between 0.5% and 3.0%, at least one glycosaminoglycan and at least one growth factor. The present invention also relates to the cartilage product obtainable through said method. Said cartilage product is useful in the treatment or prevention of wounds, ulcers, burns, psoriasis, osteoarthritis, synovitis, osteoporosis, osteopenia, diseases of the tendons and ligaments, periodontal diseases, signs of skin aging, the harmful effects of ultraviolet radiation exposure or stretch marks.

The present invention discloses one kind of arthritis treating Chinese medicine composition and its preparation process. The Chinese medicine composition contains effective components of 12 kinds of Chinese medicinal materials, including prepared aconite root, prepared aconite root, white atractylodes rhizome, clematis root, asarum herb, etc. It may be prepared into granule, tablet, capsule or other common pharmaceutical form. It has the functions of eliminating cold and wetness, warming meridian and dredging meridian, and may be used in treating rheumatic arthritis, rheumatoid arthritis, osteoarthritis and tetanic spondylosis.